Utah Medical Products (NASDAQ:UTMD) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

Shares of UTMD stock opened at $103.00 on Friday. The stock has a market capitalization of $391.78, a P/E ratio of 26.93 and a beta of 0.59. Utah Medical Products has a 12 month low of $61.55 and a 12 month high of $109.65.

Utah Medical Products (NASDAQ:UTMD) last announced its quarterly earnings data on Tuesday, January 30th. The medical instruments supplier reported $0.95 EPS for the quarter. The firm had revenue of $10.20 million during the quarter. Utah Medical Products had a return on equity of 18.85% and a net margin of 20.54%.

In other Utah Medical Products news, CEO Kevin L. Cornwell sold 1,095 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $91.01, for a total transaction of $99,655.95. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Kevin L. Cornwell sold 1,100 shares of the firm’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $93.97, for a total value of $103,367.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,169 shares of company stock valued at $1,466,903. Corporate insiders own 8.80% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC boosted its holdings in Utah Medical Products by 9.8% during the fourth quarter. Renaissance Technologies LLC now owns 212,200 shares of the medical instruments supplier’s stock worth $17,273,000 after buying an additional 18,900 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Utah Medical Products by 1.6% during the third quarter. Dimensional Fund Advisors LP now owns 162,248 shares of the medical instruments supplier’s stock worth $11,934,000 after buying an additional 2,596 shares during the last quarter. BlackRock Inc. boosted its holdings in Utah Medical Products by 2.0% during the fourth quarter. BlackRock Inc. now owns 161,775 shares of the medical instruments supplier’s stock worth $13,168,000 after buying an additional 3,164 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Utah Medical Products by 8.5% during the fourth quarter. Geode Capital Management LLC now owns 49,184 shares of the medical instruments supplier’s stock worth $4,002,000 after buying an additional 3,849 shares during the last quarter. Finally, Thomson Horstmann & Bryant Inc. bought a new position in Utah Medical Products during the fourth quarter worth about $3,543,000. Hedge funds and other institutional investors own 67.08% of the company’s stock.

About Utah Medical Products

Utah Medical Products, Inc develops, manufactures, and distributes medical devices for the healthcare industry worldwide. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD, an infant respiratory hood; and DELTRAN PLUS, a blood pressure monitoring system.

Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.